Stock Events

Stock Events

Oragenics 

0
84
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2023
Q2 2026
Next
-83.32
-82.99
-82.66
-82.32
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-8.54MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UAVP.MU. It's not an investment recommendation.
AT&T
11
T
Fuelcell Energy
11
FCEL
Coca-Cola
10
KO
Johnson & Johnson
10
JNJ

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with Oragenics in the development of novel antibiotics and therapies, including those for oral health and infectious diseases.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals, directly competing with Oragenics in areas such as infectious disease treatment.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc engages in the creation and marketing of pharmaceutical products, including vaccines and therapies for oral health, competing with Oragenics' product range.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson operates in the pharmaceutical sector, developing products that could compete with Oragenics in various therapeutic areas, including infectious diseases.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories offers a broad range of healthcare products that compete with Oragenics, especially in the diagnostics and medical devices for infectious diseases.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. focuses on biotechnological medicines, including treatments for infections, which puts it in direct competition with Oragenics' focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company whose products in infectious disease treatment and immune system enhancement compete with Oragenics.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company develops and markets pharmaceutical products for various conditions, including those that Oragenics targets, making it a competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis AG operates globally in pharmaceuticals, directly competing with Oragenics in the development and marketing of treatments for infectious diseases.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC is a multinational pharmaceutical and biopharmaceutical company, competing with Oragenics in the development of drugs for infectious diseases and other therapeutic areas.

About

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Show more...
CEO
Janet Huffman
Employees
3
Country
United States
ISIN
US6840233026
WKN
000A3D386

Listings

LSE
GB
0A64.LSE
MU
DE
UAVP.MU
STU
DE
UAVP.STU
MU
DE
UAV.MU

0 Comments

Share your thoughts

FAQ

What is Oragenics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Oragenics stocks are traded under the ticker UAVP.MU.
When is the next Oragenics earnings date?▼
Oragenics is going to release the next earnings report on November 16, 2026.
What is Oragenics revenue for the last year?▼
Oragenics revenue for the last year amounts to 0 EUR.
What is Oragenics net income for the last year?▼
UAVP.MU net income for the last year is -8.54M EUR.
How many employees does Oragenics have?▼
As of September 04, 2026, the company has 3 employees.
In which sector is Oragenics located?▼
Oragenics operates in the Health & Wellness sector.
When did Oragenics complete a stock split?▼
The last stock split for Oragenics was on January 23, 2023 with a ratio of 1:60.
Where is Oragenics headquartered?▼
Oragenics is headquartered in LAKEWOOD RANCH, United States.